In vivo T cell tumor therapy with monoclonal antibody directed to the V beta chain of T cell antigen receptor.
To test whether antibodies directed to TCR affect T cell tumor growth in vivo, mice were inoculated intravenously with C6VL tumor cells expressing V beta 6 TCR and then treated intraperitoneally with mAb specific for V beta 6 TCR. Administration of anti-V beta 6 antibody prolonged survival of mice bearing V beta 6-expressing tumor cells and it led to the induction of host immunity to the tumor cells in surviving animals. This treatment eliminated not only tumor cells bearing V beta 6 TCR but also normal host T cells expressing V beta 6 T cells receptors. However, the lack of V beta 6-expressing T cells in such treated mice did not result in generalized immune disfunction. These data demonstrate the utility of anti-TCR V segment antibody in the treatment of T cell tumors. Most importantly, since the number of V genes for the T cell antigen receptor is limited, both in man and in mouse, it should be possible to establish a panel of mAbs directed to each V gene product and use such antibodies in the treatment of T cell neoplasms.
Kanagawa
O
O
Lilly Research Laboratory, La Jolla, California 92037.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D007116:Immunization, Passive; D007167:Immunotherapy; D008213:Lymphocyte Activation; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D016693:Receptors, Antigen, T-Cell, alpha-beta; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic; D013945:Thymoma / Q000628:therapy*
D000911:Antibodies, Monoclonal; D011948:Receptors, Antigen, T-Cell; D016693:Receptors, Antigen, T-Cell, alpha-beta